Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II study for treating gastric, ovarian, endometrial, and non-small cell lung cancers.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone31-0-30-253-8800
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$37.14 million
Profitability
Miscellaneous
Employees98
Next Earnings Date12/26/2019 (Estimated)
OptionableNot Optionable
Merus (NASDAQ:MRUS) Frequently Asked Questions
What is Merus' stock symbol?
Merus trades on the NASDAQ under the ticker symbol "MRUS."
When is Merus' next earnings date?
What price target have analysts set for MRUS?
6 equities research analysts have issued 12 month target prices for Merus' shares. Their predictions range from $16.00 to $35.00. On average, they expect Merus' stock price to reach $24.00 in the next twelve months. This suggests a possible upside of 43.0% from the stock's current price. View Analyst Price Targets for Merus.
What is the consensus analysts' recommendation for Merus?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merus in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Merus.
Has Merus been receiving favorable news coverage?
Media coverage about MRUS stock has trended somewhat positive this week, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Merus earned a daily sentiment score of 0.9 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Merus.
Who are some of Merus' key competitors?
Some companies that are related to Merus include Corcept Therapeutics (CORT), Ironwood Pharmaceuticals (IRWD), G1 Therapeutics (GTHX), Supernus Pharmaceuticals (SUPN), Gossamer Bio (GOSS), Turning Point Therapeutics (TPTX), Enanta Pharmaceuticals (ENTA), Opko Health (OPK), Theravance Biopharma (TBPH), Radius Health (RDUS), BELLUS Health (BLUSF), Ra Pharmaceuticals (RARX), Innoviva (INVA), AnaptysBio (ANAB) and Epizyme (EPZM).
What other stocks do shareholders of Merus own?
Who are Merus' key executives?
Merus' management team includes the folowing people:
- Dr. Ton Logtenberg, Pres, CEO, Principal Financial Officer & Exec. Director (Age 61)
- Dr. Hennie Hoogenboom Ph.D., Co-Founder and Scientific Advisor
- Ms. Jillian Connell, VP of Investor Relations & Corp. Communications
- Mr. John de Kruif Ph.D., CTO & Sr. VP (Age 55)
- Mr. Mark Throsby Ph.D., Chief Scientific Officer & Exec. VP (Age 52)
When did Merus IPO?
(MRUS) raised $64 million in an initial public offering (IPO) on Thursday, May 19th 2016. The company issued 4,300,000 shares at $14.00-$16.00 per share. Citigroup and Jefferies served as the underwriters for the IPO and Guggenheim Securities and Wedbush PacGrow were co-managers.
Who are Merus' major shareholders?
Merus' stock is owned by a number of of retail and institutional investors. Top institutional investors include Novo Holdings A S (2.18%), Artal Group S.A. (1.54%), Morgan Stanley (0.41%), Athanor Capital LP (0.10%), Granite Investment Partners LLC (0.07%) and JPMorgan Chase & Co. (0.04%).
Which major investors are selling Merus stock?
MRUS stock was sold by a variety of institutional investors in the last quarter, including Granite Investment Partners LLC and Novo Holdings A S.
Which major investors are buying Merus stock?
MRUS stock was purchased by a variety of institutional investors in the last quarter, including Artal Group S.A., Athanor Capital LP, JPMorgan Chase & Co. and Morgan Stanley.
How do I buy shares of Merus?
Shares of MRUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Merus' stock price today?
One share of MRUS stock can currently be purchased for approximately $16.78.
How big of a company is Merus?
Merus has a market capitalization of $381.75 million and generates $37.14 million in revenue each year. The biotechnology company earns $-28,660,000.00 in net income (profit) each year or ($1.84) on an earnings per share basis. Merus employs 98 workers across the globe.View Additional Information About Merus.
What is Merus' official website?
How can I contact Merus?
Merus' mailing address is YALELAAN 62, UTRECHT P7, 3584 CM. The biotechnology company can be reached via phone at 31-0-30-253-8800 or via email at [email protected]
MarketBeat Community Rating for Merus (NASDAQ MRUS)
MarketBeat's community ratings are surveys of what our community members think about Merus and other stocks. Vote "Outperform" if you believe MRUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRUS will underperform the S&P 500 over the long term. You may vote once every thirty days.
